{"id":"W4405364934","doi":"10.1016/j.msard.2024.106114","title":"153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial","year":2024,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Multiple sclerosis; Medicine; Placebo; Relapsing remitting; Internal medicine; Pathology; Immunology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001195865,0.001063777,0.002463534,0.0003313143,0.0005022975,0.001149788,0.0007103342,0.002327519,0.01096286],"category_scores_gemma":[0.001525162,0.0003786769,0.00206337,0.0003632126,0.0007308293,0.001120193,0.0002521165,0.003730006,0.002780971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006121496,"about_ca_system_score_gemma":0.0005907191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009317487,"about_ca_topic_score_gemma":0.002458527,"domain_scores_codex":[0.9994854,0.000249435,0.0000355447,0.0000805353,0.00003923473,0.0001098854],"domain_scores_gemma":[0.9993581,0.0002347097,0.0001388989,0.00005185683,0.00004721821,0.0001692262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9087039,0.003042279,0.0009485735,0.00114733,0.002087134,0.000120681,0.00005992639,0.0004439741,0.005186363,0.0002758289,0.007116045,0.07086805],"study_design_scores_gemma":[0.9459932,0.04489578,0.004701107,0.0001022431,0.0008530773,0.00009087779,0.00003116464,0.0003383501,0.0006392859,0.000350266,0.001980847,0.00002365025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9235677,0.03647907,0.001142818,0.005885236,0.002336285,0.002302056,0.008572115,0.0007782141,0.01893663],"genre_scores_gemma":[0.9708354,0.005761913,0.001142511,0.006509996,0.001058916,0.001502997,0.00428958,0.0000757189,0.008822926],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01096286,"threshold_uncertainty_score":0.03667438,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03891098586633257,"score_gpt":0.2788187953834719,"score_spread":0.2399078095171393,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}